News | Image Guided Radiation Therapy (IGRT) | April 30, 2018

New MR pulse sequences and imaging enhancements provide cutting-edge tumor and healthy tissue visualization for MR-guided radiotherapy

ViewRay Unveils New Soft Tissue Visualization Technologies for MRIdian Linac

April 30, 2018 — ViewRay Inc. announced new magnetic resonance imaging (MRI) technologies under development for its MRIdian Linac radiotherapy system. Designed to improve tumor and soft tissue visualization, these enhancements to MRIdian's SmartVision MR image guidance are expected to further improve the precision by which radiation is delivered to treat cancer.

MRIdian's SmartVision allows oncologists to visualize tumors and surrounding organs with diagnostic-quality MR imaging during treatment delivery. Building on the current technology are new T1w and T2w MR pulse sequences, both being developed to improve high-definition visualization and enhance the contrast between cancerous and healthy tissues. Also being developed for MRIdian's SmartVision, diffusion weighted imaging (DWI) may be used to distinguish between tumor and normal tissues and potentially assess and predict tumor response to radiation therapy.

Other enhancements to MRIdian's SmartVision include a 2-times increase in MR imaging speed as compared to previous generation systems, stepping up from 4 frames to 8 frames per second. The latest enhancements under development also include 2 times higher image resolution and a 2 times improvement in MR signal-to-noise ratio (SNR) for brighter, more detailed anatomical imaging.

MRIdian continuously detects the shape and location of tumors and organs-at-risk (OAR) in real-time, and automatically turns radiation beams on and off when positional changes occur. Enabled by faster, higher-resolution imaging, the next-generation SmartVision will further support the clinician's ability to visualize healthy tissue and target the tumor.

ViewRay demonstrated the new MR pulse sequences, along with increased imaging speed and resolution, during the annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), April 21-24 in Barcelona, Spain.

The new pulse sequences, increased image resolution and imaging frame rates are currently a technology under development and only available for sales in the European Economic Area. They are works in progress and are not available for commercial sales in the United States.

For more information: www.viewray.com

 


Related Content

News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Radiology Education

Jan. 22, 2026—The American Roentgen Ray Society (ARRS) will host a live virtual symposium, "Medical Imaging for ...

Time January 28, 2026
arrow
News | Radiology Imaging

Jan.26, 2026 — SimonMed Imaging has unveiled an updated brand and the launch of SimonMed Longevity, a new division ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Stroke

Dec. 12, 2025 — Hyperfine, Inc. has announced that it has received FDA clearance for a new multi-direction diffusion ...

Time December 15, 2025
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
Subscribe Now